Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kyle Weiss

Pain Medicine Allentown, PA Doctor of Osteopathy

NPI 1902219702 CMS profile 1387303

501 Cetronia Rd Ste 125, Ste 200, Allentown, PA 18104

Open in the dashboard

General payments

$4,494

40 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kyle Weiss of Allentown, PA is reported in the CMS Open Payments database as having received $4,494 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $271 4
2024 General $347 3
2023 General $31 1
2022 General $3,638 24
2021 General $31 3
2019 General $176 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyle Weiss
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Kyle Weiss were reported at $271. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Kyle Weiss Pain Medicine median Middle half National median
2019 $176 $409 $115–$1,311 $163
2020 $0 $214 $66–$666 $114
2021 $31 $299 $84–$899 $132
2022 $3,638 $335 $103–$1,149 $149
2023 $31 $376 $114–$1,228 $160
2024 $347 $387 $115–$1,173 $164
2025 $271 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $3,830 29 payments
  2. BIOTRONIK NRO, Inc. $457 5 payments
  3. Medtronic USA, Inc. $162 4 payments
  4. SPR Therapeutics, Inc $31 1 payment
  5. Abbott Laboratories $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,000 1 payment
  2. Travel and Lodging $1,260 12 payments
  3. Food and Beverage $916 25 payments
  4. Education $318 2 payments
Products named General payments · program years 2019–2025
  1. RESTORESENSORSURESCAN $2,000 1 payment
  2. INTELLIS ADAPTIVESTIM $1,532 20 payments
  3. Prospera Not Applicable $347 3 payments
  4. INCEPTIV $161 2 payments
  5. INTELLIS Spinal Cord Neurostimulation $113 1 payment
  6. Prospera Not Applicable $110 2 payments
  7. VANTA ADAPTIVESTIM $106 3 payments
  8. ADAPTIVESTIM $33 2 payments
  9. INTELLIS Spinal Cord Neurostimulation $31 3 payments
  10. SPRINT PNS System $31 1 payment
  11. Other $30 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

471

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$6,490

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

0%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 163 $1,851
Lidocaine Generic 35 $1,534
Duloxetine Hcl Generic 92 $911
Pregabalin Generic 41 $706
Methocarbamol Generic 58 $450
Tizanidine Hcl Generic 28 $412
Diclofenac Sodium Generic 16 $353
Celecoxib Generic 22 $259
Lorazepam Generic 16 $14

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$90,286

Of which drugs: $310

Medicare patients

379

Average age 74

Services billed

3,215

240 women, 139 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Chronic kidney disease 40%
Depression 32%
Diabetes 27%
Ischemic heart disease 26%
Osteoporosis 22%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 41 2,120 $219
Injection, methylprednisolone acetate, 40 mg J1030 Office 18 23 $91

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record